Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
CDK protein kinase inhibitor SNS 032, 5 mg  

CDK protein kinase inhibitor SNS 032, 5 mg

N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide

Synonyms: BMS 387032
SNS 032 is a specific and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9

More details

PKI-SNS032-005

Availability: within 3 days

130,00 €

Background: SNS-032 was first identified as selective inhibitor of CDK2 with potent anti-tumor activity in animal models. SNS 032 is a specific and potent inhibitor of cyclin-dependent kinases (CDK2, CDK7 and CDK9 (IC50 values to be 38, 4 and 62 nM respectively and no activity against 190 additional kinases). Mechanism- based target modulation of CDKs 2, 7 and 9 resulting in inhibition of cell cycle progression and transcription, followed by apoptosis. SNS-032 may have potential in treating hematologic malignancy by abrogating oncogene addiction.

SNS 032 induces cell cycle arrest and apoptosis in tumor cell lines.

Chemical formula: C17H24N4O2S2
Molecular weight: 380.53 g/mol
Purity: >99%
Solubility: Soluble in DMSO
Appearance: White solid
CAS Number: 345627-80-7

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

DS Williamson et al. Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2. Bioorg. Med. Chem. Lett. 2005, 15(4), 863-867.

R Chen et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood, 2009, 113(19), 4637-4645.

WG Tong et al. Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. J. Clin. Oncol. 2010, 28(18), 3015-3022. 
MA Dickson and GK Schwartz. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 2009, 16(2), 36-43.

Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD.. (2004) "N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent." J Med Chem. 47(7):1719-28.

Walsby E, Lazenby M, Pepper C, Burnett AK.(2011) “The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.” Leukemia. 2011 Mar;25(3):411-9.

The following products could also be interesting for you: